Cargando…

Correction: Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493912/ https://www.ncbi.nlm.nih.gov/pubmed/34611030 http://dx.doi.org/10.1136/jitc-2021-002886corr1

Ejemplares similares

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
por: Zubiri, Leyre, et al.
Publicado: (2021)

Correction: Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
por: Kiaie, Seyed Hossein, et al.
Publicado: (2023)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Correction: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Publicado: (2021)

Correction to: Multidisciplinary Clinical Care in the Management of Patients Receiving Anti‑GD2 Immunotherapy for High‑Risk Neuroblastoma
por: Cabral, Jennifer, et al.
Publicado: (2023)

Correction: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Publicado: (2022)

Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

Correction: Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Correction: Immune checkpoint inhibitor-associated celiac disease
Publicado: (2020)

Correction: SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
Publicado: (2021)

Correction: Acute kidney injury in patients treated with immune checkpoint inhibitors
Publicado: (2023)

Correction: Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
Publicado: (2021)

Correction to: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Correction: On the mechanism of anti-CD39 immune checkpoint therapy
Publicado: (2020)

Correction: MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
Publicado: (2020)

Correction: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Publicado: (2021)

Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2023)

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Beug, Shawn T., et al.
Publicado: (2018)

Correction: On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Publicado: (2021)

Correction to: Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
por: Wu, Xiaobin, et al.
Publicado: (2021)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Correction: (68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
Publicado: (2022)

Correction: Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy
Publicado: (2021)

Correction: Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
Publicado: (2023)

Correction to: Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Publicado: (2022)

Correction: T lymphocyte-targeted immune checkpoint modulation in glioma
Publicado: (2020)

Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
Publicado: (2021)

QUALITY OF LIFE IN OLDER ADULTS RECEIVING IMMUNE CHECKPOINT INHIBITOR THERAPY
por: Hoogland, Aasha I, et al.
Publicado: (2019)

Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report
por: Liu, Shiwei, et al.
Publicado: (2022)

Correction to: Diagnostic Value of the International Society of Cardio‐Oncology Definition for Suspected Immune Checkpoint Inhibitor–Associated Myocarditis
Publicado: (2023)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy
por: El Kawkgi, Omar M., et al.
Publicado: (2020)

Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
Publicado: (2022)

Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
por: von Itzstein, Mitchell S., et al.
Publicado: (2022)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

Hematologic complications of immune checkpoint inhibitors
por: Kroll, Michael H., et al.
Publicado: (2022)

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
por: Zhang, Lilong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ildhrj1378fgre0br5i3rj4u3k